Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Oct;86(Suppl 1):21–26.

Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials.

T E Mollnes 1, V Videm 1, J Riesenfeld 1, P Garred 1, J L Svennevig 1, E Fosse 1, K Hogasen 1, M Harboe 1
PMCID: PMC1554034  PMID: 1934602

Abstract

The degree of biocompatibility of biomaterials can be evaluated using various assay systems detecting activation of the blood cascade systems, leukocytes or platelets. Activation of complement is one mechanism associated with adverse effects observed when bioincompatible materials are used. We present data showing that the terminal complement complex, an indicator of terminal pathway activation, is suitable for evaluation of biocompatibility of biomaterials such as cardiopulmonary bypass devices. Furthermore, our results suggest that bioincompatibility is improved when artificial surfaces are modified with end point attached functionally active heparin.

Full text

PDF
21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benedetti M., De Caterina R., Bionda A., Gardinali M., Cicardi M., Maffei S., Gazzetti P., Pistolesi P., Vernazza F., Michelassi C. Blood--artificial surface interactions during cardiopulmonary bypass. A comparative study of four oxygenators. Int J Artif Organs. 1990 Aug;13(8):488–497. [PubMed] [Google Scholar]
  2. Bhakdi S., Fassbender W., Hugo F., Carreno M. P., Berstecher C., Malasit P., Kazatchkine M. D. Relative inefficiency of terminal complement activation. J Immunol. 1988 Nov 1;141(9):3117–3122. [PubMed] [Google Scholar]
  3. Bhakdi S., Muhly M. Decomplementation antigen, a possible determinant of staphylococcal pathogenicity. Infect Immun. 1985 Jan;47(1):41–46. doi: 10.1128/iai.47.1.41-46.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cheung A. K. Adsorption of unactivated complement proteins by hemodialysis membranes. Am J Kidney Dis. 1989 Dec;14(6):472–477. doi: 10.1016/s0272-6386(89)80147-7. [DOI] [PubMed] [Google Scholar]
  5. Cheung A. K., Parker C. J., Wilcox L. A., Janatova J. Activation of complement by hemodialysis membranes: polyacrylonitrile binds more C3a than cuprophan. Kidney Int. 1990 Apr;37(4):1055–1059. doi: 10.1038/ki.1990.85. [DOI] [PubMed] [Google Scholar]
  6. Deppisch R., Schmitt V., Bommer J., Hänsch G. M., Ritz E., Rauterberg E. W. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int. 1990 Feb;37(2):696–706. doi: 10.1038/ki.1990.36. [DOI] [PubMed] [Google Scholar]
  7. Fosse E., Mollnes T. E., Ingvaldsen B. Complement activation during major operations with or without cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1987 Jun;93(6):860–866. [PubMed] [Google Scholar]
  8. Garred P., Mollnes T. E., Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol. 1988 Mar;27(3):329–335. doi: 10.1111/j.1365-3083.1988.tb02354.x. [DOI] [PubMed] [Google Scholar]
  9. Garred P., Olsen J., Mollnes T. E., Bilde T., Glahn B. E. Biocompatibility of urinary catheters. Effect on complement activation. Br J Urol. 1989 Apr;63(4):367–371. doi: 10.1111/j.1464-410x.1989.tb05219.x. [DOI] [PubMed] [Google Scholar]
  10. Hakim R. M., Breillatt J., Lazarus J. M., Port F. K. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med. 1984 Oct 4;311(14):878–882. doi: 10.1056/NEJM198410043111403. [DOI] [PubMed] [Google Scholar]
  11. Hugo F., Berstecher C., Krämer S., Fassbender W., Bhakdi S. In vivo clearance studies of the terminal fluid-phase complement complex in rabbits. Clin Exp Immunol. 1989 Jul;77(1):112–116. [PMC free article] [PubMed] [Google Scholar]
  12. Hänsch G. M., Seitz M., Betz M. Effect of the late complement components C5b-9 on human monocytes: release of prostanoids, oxygen radicals and of a factor inducing cell proliferation. Int Arch Allergy Appl Immunol. 1987;82(3-4):317–320. doi: 10.1159/000234216. [DOI] [PubMed] [Google Scholar]
  13. Hänsch G. M., Seitz M., Martinotti G., Betz M., Rauterberg E. W., Gemsa D. Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components. J Immunol. 1984 Oct;133(4):2145–2150. [PubMed] [Google Scholar]
  14. Imagawa D. K., Barbour S. E., Morgan B. P., Wright T. M., Shin H. S., Ramm L. E. Role of complement C9 and calcium in the generation of arachidonic acid and its metabolites from rat polymorphonuclear leukocytes. Mol Immunol. 1987 Dec;24(12):1263–1271. doi: 10.1016/0161-5890(87)90120-9. [DOI] [PubMed] [Google Scholar]
  15. Imagawa D. K., Osifchin N. E., Ramm L. E., Koga P. G., Hammer C. H., Shin H. S., Mayer M. M. Release of arachidonic acid and formation of oxygenated derivatives after complement attack on macrophages: role of channel formation. J Immunol. 1986 Jun 15;136(12):4637–4643. [PubMed] [Google Scholar]
  16. Jenne D., Stanley K. K. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J. 1985 Dec 1;4(12):3153–3157. doi: 10.1002/j.1460-2075.1985.tb04058.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kandus A., Ponikvar R., Drinovec J., Kladnik S., Ivanovich P. Anaphylatoxins C3a and C5a adsorption on acrylonitrile membrane of hollow-fiber and plate dialyzer--an in vivo study. Int J Artif Organs. 1990 Mar;13(3):176–180. [PubMed] [Google Scholar]
  18. Kirklin J. K., Westaby S., Blackstone E. H., Kirklin J. W., Chenoweth D. E., Pacifico A. D. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1983 Dec;86(6):845–857. [PubMed] [Google Scholar]
  19. Labarre D. J. Heparin-like polymer surfaces: control of coagulation and complement activation by insoluble functionalized polymers. Int J Artif Organs. 1990 Oct;13(10):651–657. [PubMed] [Google Scholar]
  20. Maillet F., Petitou M., Choay J., Kazatchkine M. D. Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol Immunol. 1988 Sep;25(9):917–923. doi: 10.1016/0161-5890(88)90130-7. [DOI] [PubMed] [Google Scholar]
  21. Moll S., De Moerloose P., Reber G., Schifferli J., Leski M. Comparison of two hemodialysis membranes, polyacrylonitrile and cellulose acetate, on complement and coagulation systems. Int J Artif Organs. 1990 May;13(5):273–279. [PubMed] [Google Scholar]
  22. Mollnes T. E. Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex. Complement. 1985;2(2-3):156–164. doi: 10.1159/000467856. [DOI] [PubMed] [Google Scholar]
  23. Mollnes T. E., Lea T., Frøland S. S., Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985 Aug;22(2):197–202. doi: 10.1111/j.1365-3083.1985.tb01871.x. [DOI] [PubMed] [Google Scholar]
  24. Moore F. D., Jr, Warner K. G., Assousa S., Valeri C. R., Khuri S. F. The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin, and hemodilution. Ann Surg. 1988 Jul;208(1):95–103. doi: 10.1097/00000658-198807000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mulzer S. R., Brash J. L. Identification of plasma proteins adsorbed to hemodialyzers during clinical use. J Biomed Mater Res. 1989 Dec;23(12):1483–1504. doi: 10.1002/jbm.820231210. [DOI] [PubMed] [Google Scholar]
  26. Nilsson L., Nilsson U., Venge P., Johansson O., Tydén H., Aberg T., Nyström S. O. Inflammatory system activation during cardiopulmonary bypass as an indicator of biocompatibility: a randomized comparison of bubble and membrane oxygenators. Scand J Thorac Cardiovasc Surg. 1990;24(1):53–58. doi: 10.3109/14017439009101824. [DOI] [PubMed] [Google Scholar]
  27. Salama A., Hugo F., Heinrich D., Höge R., Müller R., Kiefel V., Mueller-Eckhardt C., Bhakdi S. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med. 1988 Feb 18;318(7):408–414. doi: 10.1056/NEJM198802183180704. [DOI] [PubMed] [Google Scholar]
  28. Schaefer R. M., Rauterberg E. W., Deppisch R., Vienken J. Assembly of terminal SC5b-9 complement complexes: a new index of blood-membrane interaction. Miner Electrolyte Metab. 1990;16(1):73–76. [PubMed] [Google Scholar]
  29. Toomasian J. M., Hsu L. C., Hirschl R. B., Heiss K. F., Hultquist K. A., Bartlett R. H. Evaluation of Duraflo II heparin coating in prolonged extracorporeal membrane oxygenation. ASAIO Trans. 1988 Jul-Sep;34(3):410–414. [PubMed] [Google Scholar]
  30. Videm V., Fosse E., Mollnes T. E., Ellingsen O., Pedersen T., Karlsen H. Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro. J Thorac Cardiovasc Surg. 1989 May;97(5):764–770. [PubMed] [Google Scholar]
  31. Videm V., Fosse E., Mollnes T. E., Garred P., Svennevig J. L. Complement activation with bubble and membrane oxygenators in aortocoronary bypass grafting. Ann Thorac Surg. 1990 Sep;50(3):387–391. doi: 10.1016/0003-4975(90)90480-t. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES